Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 1.00 |
| ▸ | CA2 | P00918 | 3/20 | 1.00 |
| ▸ | CA12 | O43570 | 1/20 | 1.00 |
| ▸ | CA4 | P22748 | 1/20 | 1.00 |
| ▸ | CA6 | P23280 | 1/20 | 1.00 |
| ▸ | CA5A | P35218 | 1/20 | 1.00 |
| ▸ | CA7 | P43166 | 1/20 | 1.00 |
| ▸ | CA9 | Q16790 | 1/20 | 1.00 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 1.00 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7675754 | 0.81 | MAP2 (0.74) | CA1CA2CA12CA4CA6 | |
| SCHEMBL7560999 | 0.81 | ALDH1A1 (1.00) | CA1CA2CA12CA4CA6 | |
| SCHEMBL6842213 | 0.81 | MEN1 (0.73) | CA1CA2CA12CA4CA6 | |
| SCHEMBL7566685 | 0.80 | GAA (1.00) | CA1CA2CA12CA4CA6 | |
| SCHEMBL18104687 | 0.80 | MEN1 (1.00) | CA1CA2CA12CA4CA6 | |
| SCHEMBL7532767 | 0.78 | KDM4E (0.68) | CA1CA2CA12CA4CA6 | |
| SCHEMBL13174695 | 0.74 | KDM4E (0.67) | CA1CA2CA12CA4CA6 | |
| SCHEMBL18092621 | 0.73 | CA1 (0.58) | CA1CA2CA12CA4CA6 | |
| SCHEMBL7529220 | 0.72 | LMNA (0.60) | CA1CA2CA12CA4CA6 | |
| SCHEMBL7558538 | 0.72 | LMNA (0.60) | CA1CA2CA12CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-8816095-B2 | Na channels, disease, and related assays and compositions | GEORGETOWN UNIVERSITY (US) | 2014-08-26 | — | — | US | disclosed |
| US-20110230442-A1 | NA CHANNELS, DISEASE, AND RELATED ASSAYS AND COMPOSITIONS | GEORGETOWN UNIVERSITY (US) | 2011-09-22 | — | — | US | disclosed |
| EP-2343974-A2 | NA CHANNELS, DISEASE, AND RELATED ASSAYS AND COMPOSITIONS | Georgetown University (US) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010019963-A2 | NA CHANNELS, DISEASE, AND RELATED ASSAYS AND COMPOSITIONS | GEORGETOWN UNIVERSITY (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230442-A1 | NA CHANNELS, DISEASE, AND RELATED ASSAYS AND COMPOSITIONS | CACNA1C, CACNA1B, CACNA1A | CA1 333/4885CA2 179/4885CA12 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.